New Zealand's dialysis system is at breaking point, with rural and regional patients bearing a disproportionate burden — and Māori and Pasifika communities bearing the sharpest end of an inequitable system that has been chronically underfunded for decades. With 3,314 New Zealanders currently receiving dialysis and demand growing at four percent a year, a projected 30 percent surge in patients over the next ten years threatens to deepen a crisis that is already leaving people driving hours for life-sustaining treatment three times a week.

What's happening:

• Half of all renal services nationally are operating above the effective capacity threshold of four patients per machine. Auckland is the worst affected, running at six patients per machine — 150 percent capacity — with some patients finishing three-hour sessions as late as 11pm. The national average has climbed to 4.53 patients per machine.
• Rural patients face a median one-way travel time of 45 minutes per dialysis session compared to 11 minutes for urban patients, according to a December 2024 nationwide geospatial study. For many rural patients this translates to 4.5 hours of driving per week on top of treatment time, and research directly links prolonged travel to decreased quality of life and increased mortality.
• Māori and Pasifika make up roughly 25 percent of the New Zealand population but occupy 53 percent of dialysis beds, according to nephrologist Dr Curtis Walker. Māori experience kidney failure at up to three times the rate of non-Māori. Yet the equity gap in transplantation — the treatment that frees patients from dialysis — is stark: 14 per 100 non-Māori dialysis patients received a transplant in 2019 compared to 4 per 100 Māori and 3.5 per 100 Pasifika.
• In March 2026, Christchurch Hospital warned dialysis patients that treatment might be rationed — reduced from three sessions per week to two — due to acute staff and space shortages. Clinicians described this as "suboptimal care" and a "last resort." The Association of Salaried Medical Specialists called it a symptom of a national problem.
• Kidney Health New Zealand estimates New Zealand needs approximately 150 additional dialysis machines to reach the level of service provided in Australia. The number requiring dialysis has more than doubled over the last 20 years, with type 2 diabetes and high blood pressure the primary drivers — conditions that are significantly more prevalent in Māori, Pasifika, and South Asian communities.

Where the parties stand:

The National-led Government, through Health Minister Simeon Brown, has acknowledged the dialysis access problem but has framed its response in terms of system planning rather than emergency investment. Brown stated he "made expectations clear" to Health NZ following the Christchurch rationing warning, and the Government pointed to a 21 percent increase in the National Travel Assistance Scheme mileage rate in 2024 — the first increase since 2009 — as a step toward easing the burden of travel for rural patients. Health NZ's chief clinical officer Dr Richard Sullivan has conceded that "there's no doubt in some districts there has been underfunding." The Government is awaiting publication of a National Renal Dialysis Plan being developed by the Renal National Clinical Network; as of mid-2026 the plan remained in development with no firm release date.

Labour has not released a specific dialysis or kidney disease policy ahead of the 2026 election, though its health spokesperson Ayesha Verrall has focused on primary and preventive care access — critical for catching chronic kidney disease early, before it reaches the dialysis stage. The death in June 2025 of Te Pāti Māori MP Takutai Moana Natasha Kemp, who was on dialysis while waiting for a transplant, prompted renewed calls from Māori health advocates and Te Pāti Māori for dedicated investment in addressing kidney disease inequity. ACT MP Mark Cameron, who himself requires dialysis three times weekly after total kidney failure, announced in June 2026 he would leave Parliament due to his condition — giving the access crisis an unusually direct personal dimension in the parliamentary debate.

Kidney Health New Zealand has called on all parties to recognise chronic kidney disease as a long-term condition warranting dedicated funding, to urgently address haemodialysis capacity nationwide, and to support Pharmac funding for empagliflozin (an SGLT2 inhibitor shown to slow CKD progression) for non-diabetic patients — a move the organisation argues could avoid over 10,000 hospitalisations annually and deliver $1.94 in returns per dollar invested nationally.

What to watch:

• The Renal National Clinical Network's nationwide renal dialysis plan is the most significant near-term policy document. Its publication — and whether it includes binding capacity targets, rural satellite unit investment, and equity-focused workforce commitments — will determine whether the system gets ahead of the projected 30 percent demand increase.
• The 2026 general election campaign is an opportunity for parties to release specific kidney health policies. Both National and Labour have avoided making concrete dialysis funding commitments to date; watch for Te Pāti Māori and the Greens to push for equity-focused responses.
• Pharmac's decision on whether to fund empagliflozin for non-diabetic CKD patients (subject of the May 2026 Kidney Health NZ submission) could significantly slow the rate at which patients progress to needing dialysis — particularly in Māori and Pasifika communities where the drug shows the greatest proportional benefit.